Related Experiment Video
Updated: Jun 19, 2025
A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products
Published on: October 4, 2019
Pentacyclic triterpenes, potential novel therapeutic approaches for cardiovascular diseases
Dewei Peng1,2, Aizan Wang1,2, Wei Shi3,4
1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.
Insights
Pentacyclic triterpenes show promise in treating cardiovascular diseases (CVDs) due to their anti-inflammatory and antioxidant properties. Further research explores their therapeutic potential for heart and blood vessel conditions.
Area of Science:
- Pharmacology
- Cardiology
- Natural Products Chemistry
Background:
- Cardiovascular diseases (CVDs) are a leading global health concern, characterized by heart and blood vessel dysfunction.
- Current CVD therapies face limitations, with high incidence and mortality rates persisting.
- Natural compounds are emerging as a promising avenue for novel CVD treatments.
Purpose of the Study:
- To review the roles of pentacyclic triterpenoids in the prevention and treatment of CVDs.
- To summarize the pharmacological mechanisms underlying their therapeutic effects.
- To provide a comprehensive overview of triterpenoids' potential in managing cardiovascular conditions.
Main Methods:
- Literature review of studies on pentacyclic triterpenoids and cardiovascular diseases.
- Analysis of pharmacological activities, including anti-inflammatory, antioxidant, and antitumor effects.
- Synthesis of information on mechanisms of action and therapeutic applications.
Main Results:
- Pentacyclic triterpenoids possess diverse pharmacological activities beneficial for CVDs.
- Mechanisms include anti-inflammatory, antioxidant, and potentially antitumor effects.
- These compounds demonstrate significant therapeutic potential in preclinical and clinical settings.
Conclusions:
- Pentacyclic triterpenoids represent a promising class of natural compounds for CVD prevention and treatment.
- Their multifaceted pharmacological actions offer new therapeutic strategies for cardiovascular conditions.
- Further investigation into triterpenoids could lead to innovative treatments for heart and blood vessel diseases.
Abstract:
Cardiovascular diseases (CVDs) involve dysfunction of the heart and blood vessels and have become major health concerns worldwide. Multiple mechanisms may be involved in the occurrence and development of CVDs. Although therapies for CVDs are constantly being developed and applied, the incidence and mortality of CVDs remain high. The roles of natural compounds in CVD treatment are being explored, providing new approaches for the treatment of CVD. Pentacyclic triterpenes are natural compounds with a basic nucleus of 30 carbon atoms, and they have been widely studied for their potential applications in the treatment of CVDs, to which various pharmacological activities contribute, including anti-inflammatory, antioxidant, and antitumor effects. This review introduces the roles of triterpenoids in the prevention and treatment of CVDs, summarizes their potential underlying mechanisms, and provides a comprehensive overview of the therapeutic potential of triterpenoids in the management of CVDs.
More Related Videos
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
07:20Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
Published on: February 10, 2023
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...